• RxSight entered a non-exclusive collaboration with Alcon to develop adjustable presbyopia-correcting intraocular lenses for cataract patients.
• Partnership combines RxSight’s post-operative light-adjustable technology with Alcon’s PCIOL optical designs to enable post-surgery vision fine-tuning.
• RxSight will receive a $60 million upfront payment, with up to $140 million tied to development and regulatory milestones.
• Alcon will lead global commercialization; RxSight will handle development and manufacturing, earning royalties on net sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RxSight Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607061615PRIMZONEFULLFEED9757545) on July 06, 2026, and is solely responsible for the information contained therein.